MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, received an order suspending a Drug License for a store located in Karnataka. The suspension was ordered by the Assistant Director, Drugs Control Administration, Hubli Circle. The adverse impact is quantified as a potential revenue loss of ₹0.66 lacs, which the company deems quantifiable in monetary terms to the extent possible.
Disclosure of Regulatory Action
MedPlus Health Services Limited has formally communicated an update regarding regulatory action impacting one of its operational units. The company wishes to inform the exchanges that Optival Health Solutions Private Limited, a subsidiary, has been subject to an order concerning a Drug License.
Details of License Suspension
The authority that issued the order was the Assistant Director, Drugs Control Administration, Hubli Circle, Hubli, Karnataka. The nature of the action taken was the Suspension of Drug License for a store located at Kalyan Nagar Dharwad, Karnataka.
The order was officially received by the company on March 27, 2026. The suspension pertains to a duration of three days.
Governing Rules and Financial Impact
The action was taken under the provisions of Rule 65 of the Drugs and Cosmetics Act, 1940, and related rules. The company has assessed the immediate financial consequence of this temporary disruption.
The calculated impact on the entity’s operations is a Potential Revenue Loss of Rs 0.66 lacs. This figure represents the quantifiable impact of the suspension on the listed entity’s activities for the affected period.
Source: BSE
